Mark Peterson
Papers
1
Total Citations
33
H-Index
1
About
Mark Peterson is a leading translational scientist whose work bridges clinical biomarkers and therapeutic development, particularly in bone and metabolic diseases. His key research areas include biomarker validation, osteoporosis, and the pharmacology of monoclonal antibody therapies. Peterson’s most notable contribution is his seminal 2009 paper on the “fit-for-purpose” validation of C-terminal telopeptides of type 1 collagen (CTX-1) as a biomarker in denosumab clinical studies. This work established a rigorous framework for using bone turnover markers in drug development, directly enabling the successful clinical trials that led to denosumab’s approval for osteoporosis. With 33 citations, the paper remains a cornerstone in biomarker methodology, demonstrating how targeted validation can accelerate regulatory decisions. Peterson’s impact extends beyond this single study; his collaborative efforts have shaped best practices for integrating biomarkers into late-stage clinical programs, influencing both academic research and pharmaceutical industry standards. His achievements highlight the critical role of methodical biomarker science in translating biological insights into life-changing therapies.
Research Focus
Key Achievements
Top Papers
- 1